This Article Full Text Full Text (PDF) All Versions of this Article: 118/4/355    most recent CIRCULATIONAHA.108.773267v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Medina, M. W. Articles by Krauss, R. M. Search for Related Content PubMed PubMed Citation Articles by Medina, M. W. Articles by Krauss, R. M. Related Collections Lipids Primary prevention Risk Factors Gene expression Gene regulation Lipid and lipoprotein metabolism Related Article

(Circulation. 2008;118:355-362.)
© 2008 American Heart Association, Inc.

Genetics

Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated With Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin

Marisa Wong Medina, PhD; Feng Gao, MS; Weiming Ruan, PhD; Jerome I. Rotter, MD; Ronald M. Krauss, MD

From the Children’s Hospital Oakland Research Institute, Oakland (M.W.M., F.G., W.R., R.M.K.), and Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles (J.I.R.), Calif.

Correspondence to Dr Ronald Krauss, Children’s Hospital Oakland Research Institute, 5700 Martin Luther King Jr Way, Oakland, CA 94609. E-mail rkrauss{at}chori.org

Received February 14, 2008; accepted May 22, 2008.

Background— HMGCR(3-Hydroxy-3-methylglutaryl coenzyme A reductase), the direct target of statin inhibition, undergoes alternative splicing of exon 13, which encodes part of the statin-binding domain of the enzyme. We hypothesized that HMGCR alternative splicing might be related to the interindividual variation in plasma low-density lipoprotein cholesterol response to statin treatment.

Methods and Results— We measured mRNA expression of both the full-length and the alternatively spliced HMGCR transcript lacking exon 13 (HMGCRv_1) in 170 simvastatin-incubated immortalized lymphocyte cell lines derived from participants in the Cholesterol and Pharmacogenetics (CAP) study who were treated with simvastatin 40 mg/d for 6 weeks. Greater upregulation of HMGCRv_1 in vitro was significantly correlated (P0.0001) with smaller in vivo reductions of plasma total cholesterol, low-density lipoprotein cholesterol, apoprotein B, and triglycerides and explained 6% to 15% of the variation in their response to treatment. In contrast, no significant relationship was found between expression of the full-length HMGCR transcript and in vivo response. By siRNA knockdown of the full-length transcript, we found that HMGCR enzyme activity measured in cells enriched in HMGCRv_1 was relatively resistant to statin inhibition, consistent with the association of increased alternative splicing with reduced statin response in the CAP study. In addition, we found that a common HMGCR single-nucleotide polymorphism (rs3846662) located within intron 13 was associated with variation in the proportion of HMGCR mRNA that is alternatively spliced.

Conclusions— Variation in the production of an HMGCR isoform with reduced statin sensitivity is a determinant of interindividual differences in low-density lipoprotein cholesterol, apolipoprotein B, and triglyceride response to statin treatment.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 321-322. [Extract] [Full Text]

This article has been cited by other articles:

				J. F. Thompson, C. L. Hyde, L. S. Wood, S. A. Paciga, D. A. Hinds, D. R. Cox, G. K. Hovingh, and J. J.P. Kastelein Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort Circ Cardiovasc Genet, April 1, 2009; 2(2): 173 - 181. [Abstract] [Full Text] [PDF]